Welcome to our dedicated page for Myomo SEC filings (Ticker: MYO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Myomo, Inc. (NYSE American: MYO) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Myomo is a wearable medical robotics company that develops and markets MyoPro myoelectric orthoses for individuals with neuromuscular disorders and upper-limb paralysis, and its filings offer detailed insight into how this business is structured and financed.
Through documents such as annual reports on Form 10-K and quarterly reports on Form 10-Q, Myomo reports information on revenue from MyoPro devices, gross margin, operating expenses, cash position and risk factors related to reimbursement, financing, product development and regulatory approvals. These filings also describe the company’s focus on its MyoPro product line, its relationships with orthotics and prosthetics providers and the Veterans Health Administration, and its dependence on third-party payers such as Medicare Part B and private insurers.
Current reports on Form 8-K document specific material events. For example, Myomo has filed 8-Ks describing a Loan and Security Agreement that provides term loans secured by a lien on the company’s assets, including intellectual property, together with associated warrants to purchase common stock and potential conversion rights. Another 8-K outlines a salary-for-restricted stock units program for certain executives. These filings explain key terms such as interest-only periods, maturity dates, financial covenants and equity-related features.
On Stock Titan, users can view these filings as they are made available from EDGAR and use AI-powered summaries to understand complex sections, including capital structure provisions, debt covenants, warrant terms and equity compensation arrangements. The page also surfaces Form 4 and other ownership-related filings, helping users monitor insider transactions and changes in beneficial ownership alongside the company’s broader financial and operational disclosures.
Myomo, Inc. received an amended Schedule 13G from investment firm Rosalind Advisors, Inc., its fund Rosalind Master Fund L.P., and principals Steven Salamon and Gilad Aharon. They report beneficial ownership of 3,839,772 Myomo common shares, or about 9.99%, based on 38,435,524 shares outstanding as of November 3, 2025.
The group also holds pre-funded warrants for an additional 3,763,258 shares, but a 9.99% ownership blocker prevents exercising these warrants while their stake is at that level. The filers state the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Myomo.
Myomo, Inc. reported that Chief Executive Officer and director Paul R. Gudonis received a grant of 11,637 shares of common stock on January 12, 2026 at a price of $0 per share. After this grant, he beneficially owned 1,260,650 shares of Myomo common stock in direct form.
The shares represent Restricted Stock Units under a Board-approved program that allows employees to forego 10% of their salary in exchange for RSUs with a grant date fair value of 115% of the salary exchanged. This particular grant covers three months of salary, and the RSUs vest in full on April 12, 2026.
Myomo, Inc. reported a new equity award to its Chief Financial Officer, David A. Henry. On January 12, 2026, he acquired 8,727 shares of common stock at a stated price of
According to the footnote, the award represents Restricted Stock Units granted under a Board-approved program that allows employees to forego 10% of their salary in exchange for RSUs with a grant date fair value of 115% of the salary exchanged. This particular grant covers three months of salary and the RSUs vest in full on April 12, 2026.
Myomo, Inc. received a significant ownership disclosure from Horton Capital affiliates and Joseph M. Manko, Jr. They report beneficial ownership of 1,960,212 common shares, or approximately 5.1% of Myomo’s outstanding stock, based on 38,435,524 shares as of November 3, 2025. The position was acquired by Horton Capital Partners Fund, LP for an aggregate purchase price of about $3,311,165, using working capital.
The investors state they bought the shares because they viewed them as undervalued and as an attractive investment. They indicate they may buy more or sell shares depending on market conditions and Myomo’s performance. The group is actively engaging with Myomo’s management, board, other shareholders, and third parties on topics such as strategy, capital structure, and governance.
Horton Capital submitted a shareholder proposal for Myomo’s 2026 annual meeting, requesting that the board eliminate its classified structure so that all directors are elected annually beginning at or after the 2026 meeting, signaling a focus on board governance and shareholder influence.
Myomo, Inc. disclosed that its Compensation Committee approved a 2026 salary-for-restricted stock unit program open to all salaried employees. CEO Paul Gudonis and CFO David Henry each voluntarily elected to reduce their 2026 base salary by 10% in exchange for RSUs with an aggregate grant date fair value equal to 115% of the salary foregone, or $40,000 for the CEO and $30,000 for the CFO.
The company may, in its sole discretion, terminate or modify this program at any time before January 12, 2026; if it does, no RSUs will be granted and base salaries will remain unchanged. Subject to that right, RSUs will be granted in equal quarterly installments beginning January 12, 2026, with each quarterly grant vesting in full three months after its grant date under the company’s 2018 Stock Option and Incentive Plan and the applicable RSU agreements, provided the officer remains in continuous service.
Myomo, Inc. (MYO)
Myomo, Inc. director reports open-market share purchases on a Form 4. The reporting person bought 4,000 shares of Myomo common stock on 11/18/2025 at a price of $0.7345 per share in a single open-market transaction. On 11/19/2025, an additional 385 shares were purchased at a weighted average price of $0.765 per share. Following these transactions, the reporting person beneficially owned 75,748 shares directly and 479 shares indirectly through an immediate family member, for which beneficial ownership is disclaimed except to the extent of any pecuniary interest.
Myomo, Inc. received an amended Schedule 13G reporting that Rosalind Advisors, Rosalind Master Fund L.P., Steven Salamon, and Gilad Aharon collectively beneficially own 9.9% of Myomo’s common stock. The filing references 38,435,524 shares outstanding as of November 3, 2025.
The reported position reflects 3,790,788 shares of common stock and an additional 3,763,258 pre-funded warrants that are subject to a 9.99% “blocker”, which prevents exercises that would push ownership above that level. As a result, the warrants were not exercisable as of the event date, and the reporting persons indicate passive intent under Schedule 13G certifications.
Myomo, Inc. reported Q3 2025 results with revenue of $10.09 million, up from $9.21 million a year ago. Gross margin declined to 63.8% from 75.4% as higher material costs, increased manufacturing overhead tied to the new headquarters, and less capitalized overhead weighed on profitability. The quarter’s operating loss was $3.52 million, and net loss was $3.66 million (basic and diluted loss per share $0.09).
For the nine months, revenue reached $29.57 million versus $20.48 million last year, while net loss was $11.76 million. Cash and cash equivalents were $12.55 million at September 30, 2025. Operating cash outflow was $13.37 million year‑to‑date. On the balance sheet, the company had $1.0 million outstanding on its revolving credit line and $3.0 million under its term loan facility.
After quarter‑end, Myomo entered a new loan agreement providing up to $17.5 million in committed capital, with $12.5 million funded on November 4, 2025. Management states current cash and expected cash flows are sufficient to fund operations for at least the next twelve months. Shares outstanding were 38,435,524 as of November 3, 2025.
Myomo, Inc. entered a new senior secured Loan and Security Agreement with Avenue on November 4, 2025, providing committed term loans of up to $17.5 million. The company received $12.5 million at closing (Tranche 1), with up to $5.0 million available between November 4, 2026 and May 4, 2027, subject to no default. By mutual agreement, a discretionary tranche could add up to $10.0 million in 2027. The loans bear interest at 4.75% + WSJ prime (with a prime floor set on the closing date) and mature on June 1, 2029. Interest-only runs for 18 months after closing, extendable six months if Tranche 2 funds. The facility is secured by a senior lien on all assets, including IP.
Prepayment fees are 3.0%/2.0%/1.0% by anniversary, plus a 3.25% final payment fee at maturity or earlier prepayment. Covenants require at least $2.5 million of unrestricted cash, achieving ≥75% of trailing three‑month projected revenue, and limiting trailing six‑month cash burn to the greater of 150% of projected or $2.0 million. The lender may convert up to $3.0 million of Tranche 1 and $1.0 million of Tranche 2 into common stock at 120% of the warrant exercise price and holds a $1.0 million equity participation right. Myomo also issued a warrant to purchase up to $1,312,500 worth of common stock, exercisable at the lesser of $0.96 or the next bona fide equity round price before June 30, 2026, expiring November 4, 2030. A Q3 2025 results press release was furnished as Exhibit 99.1.
FAQ
What is the current stock price of Myomo (MYO)?
What is the market cap of Myomo (MYO)?
